Ascentage Pharma Group Stock Net Income
| ASPHF Stock | USD 8.48 0.00 0.00% |
Fundamental analysis of Ascentage Pharma allows traders to better anticipate movements in Ascentage Pharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Ascentage |
Ascentage Pharma Group Company Net Income Analysis
Ascentage Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Ascentage Pharma Net Income | (782.42 M) |
Most of Ascentage Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascentage Pharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Ascentage Pharma Group reported net income of (782.42 Million). This is 329.26% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is significantly higher than that of the company.
Ascentage Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascentage Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ascentage Pharma could also be used in its relative valuation, which is a method of valuing Ascentage Pharma by comparing valuation metrics of similar companies.Ascentage Pharma is currently under evaluation in net income category among its peers.
Ascentage Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.63) % | |||
| Current Valuation | 844.8 M | |||
| Shares Outstanding | 287.77 M | |||
| Shares Owned By Insiders | 26.81 % | |||
| Shares Owned By Institutions | 11.60 % | |||
| Price To Book | 12.28 X | |||
| Price To Sales | 14.53 X | |||
| Revenue | 27.91 M | |||
| Gross Profit | 24.58 M | |||
| EBITDA | (802.15 M) | |||
| Net Income | (782.42 M) | |||
| Total Debt | 1.03 B | |||
| Book Value Per Share | 3.39 X | |||
| Cash Flow From Operations | (604.68 M) | |||
| Earnings Per Share | (0.46) X | |||
| Number Of Employees | 600 | |||
| Beta | 1.34 | |||
| Market Capitalization | 1.18 B | |||
| Total Asset | 2.94 B | |||
| Z Score | 0.6 | |||
| Net Asset | 2.94 B |
About Ascentage Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascentage Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascentage Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascentage Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Additional Information and Resources on Investing in Ascentage Pink Sheet
When determining whether Ascentage Pharma is a strong investment it is important to analyze Ascentage Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascentage Pharma's future performance. For an informed investment choice regarding Ascentage Pink Sheet, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascentage Pharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.